

CITATION REPORT

List of articles citing

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020

DOI: 10.1001/jamanetworkopen.2022.25973
, 2022, 5, e2225973.

Source: <https://exaly.com/paper-pdf/150135973/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology. 2022 , 20,		0
5	Newly approved cancer drugs in China Innovation and clinical benefit.		0
4	The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: A comparative analysis. 2022 , 100670		0
3	Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020. 11,		0
2	Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China. 14,		0
1	Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement.		0